Trial leaders recognize traditional site initiation processes often lead to excessive delays but have struggled to adapt and improve.
They know that delays in study startup mean patients must wait even longer to access critical treatments. They also know that delays in activating sites can add between $600,000 to $8 million
2021 was a historic year in the battle to defeat cancer.
More novel cancer treatments became available than ever before with the number of Oncology specific clinical trials also reaching an all-time high, up 56% from 2016 and mostly focused on rare cancer indications.
With global spending on Oncology expected to exceed $300
Atul Mahableshwarkar, M.D., DFAPA, joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss clinical trial methodology. A self-described “trial nerd,” Atul illuminates the make-or-break role methodology plays in a trial’s success and shares his advice and best practices for making positive outcomes possible.
Enjoy this interview
The area of clinical research known as CNS (central nervous system conditions) is commonly cited for its complexity and the subjective nature of many assessment tools. CNS clinicians therefore must commit to tackling unique challenges affecting their patients and the research they conduct.
It should be no surprise that the life
Jennifer Brandl joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss the feasibility and pros and cons of virtual site initiation visits. A clinical operations expert with a passion for data science, Jennifer shares her experience transitioning from pre-clinical to clinical research and her confidence
It’s impossible to read an industry publication without hearing about virtual clinical trials, decentralized clinical trials, or hybrid trials. Industry leaders and technology companies are touting the advantages and the opportunities to anyone who will listen. You may understand the model, and you may recognize the effort to shift. But
Updated 16 November 2021.
The clinical operations conference landscape was nothing if not fluid in 2021, so you may be wondering what events focused on clinical research will remain on the calendar. Though many conferences and meetings have gone virtual, many are emerging as in-person or hybrid this year.
To help you
Peju Oshisanya joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss diversity and inclusion in clinical trials. An experienced clinical operations specialist and a strong advocate for data diversity, Peju shares her insight into the health sciences industry, evaluates opportunities for improvement, and illuminates the